Morningstar Investment Services LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
Morningstar Investment Services LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q1 2022$202,0000.0%5,012
-0.4%
0.00%0.0%
Q4 2021$202,000
-11.8%
5,031
+0.6%
0.00%
-33.3%
Q2 2021$229,000
+11.7%
5,0000.0%0.00%0.0%
Q1 2021$205,000
-4.2%
5,0000.0%0.00%0.0%
Q4 2020$214,000
+20.9%
5,000
-50.0%
0.00%0.0%
Q4 2019$177,000
+14.2%
10,0000.0%0.00%0.0%
Q3 2019$155,000
-9.9%
10,0000.0%0.00%0.0%
Q2 2019$172,000
+6.8%
10,0000.0%0.00%0.0%
Q1 2019$161,000
+10.3%
10,0000.0%0.00%0.0%
Q4 2018$146,000
-19.8%
10,0000.0%0.00%0.0%
Q3 2018$182,000
+7.7%
10,0000.0%0.00%0.0%
Q2 2018$169,000
-13.8%
10,0000.0%0.00%
-25.0%
Q1 2018$196,000
-3.4%
10,0000.0%0.00%0.0%
Q4 2017$203,000
+16.7%
10,0000.0%0.00%0.0%
Q3 2017$174,000
+35.9%
10,0000.0%0.00%
+33.3%
Q2 2017$128,000
-1.5%
10,0000.0%0.00%0.0%
Q1 2017$130,000
+31.3%
10,0000.0%0.00%0.0%
Q4 2016$99,000
-18.2%
10,0000.0%0.00%0.0%
Q3 2016$121,000
+33.0%
10,0000.0%0.00%0.0%
Q2 2016$91,000
-4.2%
10,0000.0%0.00%0.0%
Q1 2016$95,000
-45.1%
10,0000.0%0.00%
-57.1%
Q4 2015$173,000
+29.1%
10,0000.0%0.01%
+16.7%
Q3 2015$134,000
-40.7%
10,0000.0%0.01%
-40.0%
Q2 2015$226,000
+26.3%
10,000
-20.0%
0.01%
+25.0%
Q1 2015$179,000
-17.5%
12,500
-44.4%
0.01%
-20.0%
Q4 2014$217,00022,5000.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders